AKT1 and neoplasm: The aim of this study was to analyze EGFR-dependent Akt and mTORC1 signaling in treatment-naïve tumor samples of the OSAG 101-BSA-05 patient cohort as a potential predictive biomarker of nimotuzumab efficacy.